Tazobactum%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin is a broad-spectrum penicillin antibiotic. Tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by many bacterial beta-lactamases, extending its spectrum of activity to include many gram-negative and anaerobic organisms. ## Primary Indications * Complicated intra-abdominal infections (cIAI) * Complicated skin and skin structure infections (cSSSI) * Community-acquired pneumonia (CAP) * Nosocomial pneumonia (HAP) * Febrile neutropenia (as part of combination therapy) * Bacterial infections caused by piperacillin-susceptible organisms, in combination with an appropriate antibiotic, when other agents are inappropriate. ## Adult Dosing * **Standard Dosing:** 3.375 g (3 g piperacillin/0.375 g tazobactam) or 4.5 g (4 g piperacillin/0.5 g tazobactam) intravenously every 6 or 8 hours. * **Dosage depends on severity of infection and indication.** Higher doses (e.g., 4.5 g every 6 hours) are often used for severe infections, hospital-acquired pneumonia, or febrile neutropenia. * **Maximum dose:** Generally 18 g per day (e.g., 4.5 g every 6 hours). ## Pediatric Dosing Dosing varies significantly by indication, patient weight, and age. **Consult specific pediatric guidelines or protocols.** * **Infants and Children (≥ 1 year):** Typical doses range from 80 mg piperacillin/10 mg tazobactam per kg per dose to 120 mg piperacillin/15 mg tazobactam per kg per dose, administered every 6 or 8 hours. Maximum single doses should not exceed adult doses. * **Neonates and Infants (< 1 year):** Dosing is complex and based on weight and gestational age. **Extensive caution and specific neonatal guidelines are required.** ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No adjustment needed. * CrCl 20-40 mL/min: Administer at the same frequency but reduce the dose by 25%. * CrCl < 20 mL/min: Administer at the same frequency but reduce the dose by 50%. * **For patients on intermittent hemodialysis:** Administer a dose after each dialysis session. * **Hepatic Impairment:** No dose adjustment is typically recommended, but caution may be warranted in severe hepatic insufficiency. ## Contraindications * Known severe hypersensitivity to piperacillin, tazobactam, other penicillins, or beta-lactamase inhibitors. * History of allergic reaction to cephalosporins may indicate cross-reactivity. ## Adverse Effects * **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, phlebitis/thrombophlebitis at the injection site. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis), seizures (especially with high doses or renal impairment), interstitial nephritis, hepatic dysfunction, hematologic changes (neutropenia, eosinophilia, thrombocytopenia, leukopenia, anemia), neuromuscular excitability. ## Key Drug Interactions * **Aminoglycosides:** Potential for antagonism, but often used synergistically. Monitor drug levels and efficacy. * **Probenecid:** Decreases renal excretion of piperacillin, increasing serum levels. * **Neuromuscular Blockers (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade. * **Warfarin:** May decrease the effect of warfarin, increasing the risk of bleeding. Monitor INR closely. * **Live attenuated bacterial vaccines:** May reduce the efficacy. ## Monitoring * **Renal function:** Especially in patients with pre-existing renal impairment or those receiving other nephrotoxic agents. * **Liver function tests:** Baseline and periodically. * **Complete blood count:** To monitor for hematologic changes. * **Signs and symptoms of infection:** Clinical response to therapy. * **Signs and symptoms of hypersensitivity reactions.** * **INR:** If co-administered with warfarin. ## Clinical Pearls * Piperacillin-tazobactam is often reserved for moderate to severe infections due to its broad spectrum. * It is frequently used in hospital settings for empiric coverage of Gram-negative rods and anaerobes. * Ensure adequate hydration and monitor for signs of renal toxicity, especially in elderly patients or those with renal dysfunction. * Discontinue if diarrhea suggestive of *C. difficile* infection occurs. * Reconstituted solutions are typically stable for 24 hours at room temperature or 48 hours under refrigeration. Consult product labeling for specific stability information. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your institution's protocols before making any treatment decisions.